Efficacy of a Tumor Microenvironment-Responsive Oncolytic Adenovirus in Various Gynecological Preclinical Cancer Models

More than one million women worldwide are diagnosed with gynecological cancer each year.Most cases are detected at a late stage, either due to a lack of symptoms, as seen in ovarian cancer, or limited access to primary prevention in lowresource countries, as in cervical cancer.In this study, we further investigate AR2011, a stroma-targeted, tumor microenvironment-responsive oncolytic adenovirus (OAdV) driven by a triple-hybrid promoter.We demonstrate that AR2011 effectively replicates and induces lysis in fresh in vitro explants derived from human ovarian, uterine, and cervical cancers.Additionally, AR2011 significantly inhibits the in vitro growth of malignant ovarian cells obtained from human ascites fluid.